aTYR PHARMA (ATYR) Retained Earnings (2014 - 2026)

aTYR PHARMA (ATYR) has reported Retained Earnings for 13 consecutive years, with $676.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 5.42% year-over-year to $676.0 million; the trailing twelve-month figure through Jun 2026 stood at $676.0 million (up 5.42% YoY), and the FY2025 full-year result was $673.6 million, up 11.88% from the prior year.
• Retained Earnings steadied at $676.0 million in Q2 2026 per ATYR's latest filing, from $674.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $676.0 million in Q2 2026 and bottomed at $483.7 million in Q1 2022.
• Historically, Retained Earnings has averaged $579.9 million across 5 years, with a median of $574.8 million in 2024.
• The widest YoY moves for Retained Earnings: up 22.33% in 2022, down 1.36% in 2022.
• Over 5 years, Retained Earnings stood at $489.5 million in 2022, then advanced by 14.13% to $558.7 million in 2023, then climbed by 7.76% to $602.0 million in 2024, then grew by 11.88% to $673.6 million in 2025, then rose by 0.37% to $676.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $676.0 million, $674.9 million, and $673.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.